BioSpace News Archive

RELIEF THERAPEUTICS Holding SA reported that the parent company of its U.S. collaboration partner, NRx Pharmaceuticals, Inc., provided a safety update on ZYESAMI which is being tested in the ACTIV-3 Critical Care Phase 3 study sponsored by the National Institutes of Health.

The ocular diseases are prevented and can be easily detected with the help of tools in the automated visual field.

Oncopeptides AB, a global biotech company focused on the development of therapies for difficult-to-treat hematological diseases, has published the report for the second quarter 2021.

BioRestorative Therapies, Inc., a life sciences company focused on stem cell-based therapies, announced that it has been named one of the Top 10 Spine Device Companies and featured by MedTech Outlook, a leading print and digital magazine that provides details and insights regarding novel and high impact medical technologies.

PharmaCyte Biotech, Inc. today announced that it has entered into definitive agreements with institutional investors for the purchase and sale, in a registered direct offering priced at-the-marked under Nasdaq rules.

Humacyte, Inc announced today the successful completion of its 13th Expanded Access Program (EAP) implant of its bioengineered blood vessel, the Human Acellular Vessel (HAV), in the U.S.

Oncology Pharma Inc. has finalized a Co-Development Agreement with NanoSmart Pharmaceuticals, Inc.

NLS Pharmaceutics Ltd., a Swiss clinical-stage pharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders, announces that it has received a Notice of Allowance from the U.S. Patent and Trademark Office for patent application No. 16/083,131.

Ensysce Biosciences, Inc. (“Ensysce” or the “Company”) (NASDAQ: ENSC, OTC: ENSCW), a clinical-stage biotech company with proprietary technology platforms to reduce the economic and social burden of prescription drug abuse and overdose, today announced it will sponsor a satellite symposium at PAINWeek 2021 on Thursday, September 9 from 3:40 p.m. to 4:30 p.m. Eastern Time (12:40 p.m. to 1:30 p.m. Pacific Time) in Castellana 1 Ballroom, The Cosmopolitan of Las Vegas

Inovalon today announced that it has entered into a definitive agreement to be acquired by an equity consortium led by Nordic Capital, and joined by Insight Partners